Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CHEK

Check-Cap (CHEK) Stock Price, News & Analysis

Check-Cap logo

About Check-Cap Stock (NASDAQ:CHEK)

Key Stats

Today's Range
$1.50
▼
$1.67
50-Day Range
$1.21
▼
$1.98
52-Week Range
$0.59
▼
$3.13
Volume
58,962 shs
Average Volume
1.29 million shs
Market Capitalization
$9.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Check-Cap Ltd. (NASDAQ: CHEK) is a clinical-stage medical device company focused on the development of non-invasive screening technologies for colorectal cancer. The company’s lead product, the C-Scan® system, is designed to provide a full-colonic 360° visualization by combining an ingestible X-ray emitting capsule with an external detector array and proprietary image reconstruction algorithms. Intended as a minimally invasive alternative to traditional colonoscopy, the C-Scan system aims to improve patient comfort and compliance while maintaining high sensitivity for detecting polyps and early-stage lesions.

The C-Scan procedure involves the patient ingesting the capsule, which passes naturally through the gastrointestinal tract. During its transit, the capsule emits low-dose X-rays that are captured by detectors worn externally around the abdomen. Data collected by the system are then processed by software to generate high-resolution, panoramic images of the colon lining. This approach seeks to address limitations of stool-based tests and virtual colonoscopy, offering clinicians detailed anatomical views without sedation or insufflation.

Founded in Israel, Check-Cap maintains its headquarters in Caesarea along with operations in the United States, where it conducts clinical trials and regulatory activities. The company has completed multiple early-stage studies and has been advancing toward pivotal trials required for regulatory clearances in both European and U.S. markets. Check-Cap’s development strategy includes collaborations with leading gastroenterology centers to validate clinical efficacy and support future commercial rollout.

Check-Cap is led by a management team with extensive experience in medical imaging, device development and gastroenterology. The company continues to advance its C-Scan platform through ongoing research, regulatory engagement and strategic partnerships, aiming to transform colorectal cancer screening by offering a patient-friendly solution with broad applicability in routine preventive care.

AI Generated. May Contain Errors.

Receive CHEK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Check-Cap and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CHEK Stock News Headlines

Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
3 Penny Stocks to Watch Now, 1/27/26
See More Headlines

CHEK Stock Analysis - Frequently Asked Questions

Check-Cap Ltd. (NASDAQ:CHEK) released its earnings results on Monday, November, 27th. The medical research company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.39.

Shares of Check-Cap reverse split on Friday, November 25th 2022.The 1-20 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Check-Cap (CHEK) raised $13 million in an initial public offering (IPO) on Thursday, February 19th 2015. The company issued 1,200,000 shares at $10.00-$12.00 per share. Chardan Capital Markets and Maxim Group acted as the underwriters for the IPO and Feltl and Company was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Check-Cap investors own include Bionano Genomics (BNGO), NIO (NIO), Palantir Technologies (PLTR), Plug Power (PLUG), SNDL (SNDL), NVIDIA (NVDA) and Ocugen (OCGN).

Company Calendar

Last Earnings
11/27/2023
Today
10/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:CHEK
CIK
1610590
Employees
80
Year Founded
2005

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.25) per share
Price / Book
-6.46

Miscellaneous

Outstanding Shares
5,851,000
Free Float
5,823,000
Market Cap
$9.45 million
Optionable
Not Optionable
Beta
0.41

Social Links

The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:CHEK) was last updated on 11/26/2025 by MarketBeat.com Staff.
From Our Partners